DIACC2020 / Evexta Bio - LARVOL DELTA

Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs) (GlobeNewswire) - "Diaccurate...announced it received from Bpifrance a grant termed 'Aide à l’Innovation' to support its DIACC2020 Program aiming to establish the preclinical proof-of-concept of its sole-in-class molecule DIACC2010 as a next-generation payload for ADCs, for the treatment of solid and hematologic tumors....The workplan will run for 18 months up to the preclinical proof-of-concept in at least two models of human tumors. Preliminary efficacy and toxicity results will be available by the end of 2023 and will support potential license agreements with pharmaceutical companies."

Financing • Preclinical • Hematological Malignancies • Oncology • Solid Tumor